Front Page - EMeRGe

We conduct research in the following areas:

• pharmacoepidemiology using large electronic health record datasets and disease registers

• identification and prevention of adverse drug events

• adherence to medication and related to health outcome

• disease epidemiology (breast cancer, cardiovascular disease)

• population health and health services research

• health behaviour change methods

We work with healthcare professionals, regulatory authorities, decision makers, researchers and patient representatives to address research questions and evidence of most relevance at the population level. Our backgrounds are in pharmacy, statistics, psychology, epidemiology, health service research and translational medicine.

Our research is currently funded by the Health Research Board, Research Leaders Award (RL-15-1579), KEDs award (KED-17-012) and an Applied Partnership Award (APA-2017-0015).

About EMeRGe and our Mission

EMeRGe is an epidemiology research group led by Prof Kathleen Bennett at RCSI, Dublin.

The main pillars of research within EMeRGe include:

Safe and Quality Medicines

Adherence

Cancer epidemiology

Other disease modelling

Here at EMeRGe, our mission is to improve population health outcomes through research evidence and to translate the evidence into effective decision making for policy and practice. In particular, to: promote safe, quality and effective medicines management and model disease epidemiology in cancer and cardiovascular disease.

Click Here to Discover More About Emerge

Our Research

There are four main pillars of research within the EMeRGe research group.

Click on the icons to find our more about our research areas.

Safe & Quality Medicines

Prescribing of medicines is the most common healthcare intervention. Our research provides data and evidence on population based estimates and risk prediction of adverse drug events (ADEs) in the primary and secondary care settings. It includes the ADAPT study which is a prospective study examining the prevalence of ADRs in hospital admissions following an adverse drug event. It also includes research using large epidemiological studies of high risk medicines and associated outcomes.

Adherence

Medication adherence is the process by which patients consume their medications as prescribed by healthcare providers consisting of three distinct, yet inter-related phases; initiation, implementation and discontinuation.

Cancer Epidemiology

Cancer Epidemiology is the study of the distribution and determinants of the likelihood of cancer development. The research group have a particular focus on determinants and interventions in breast cancer, but also colorectal disease.

Other Disease Modelling

Modelling the underlying disease process and associated outcomes can help inform policy and practice by providing evidence on the potential effectiveness of interventions, or projected long term trends for planning. Previous research in this area has been in coronary heart disease (CHD IMPACT model) and the impact of health policies on influencing health determinants.

Study Publications

PDF Download

Recent study publications will be displayed here.

For full publication list click on the below link. Study Publications Full List

Medication Adherence

Walsh CA, Mucherino S, Orlando V et al. Mapping the use of Group-Based Trajectory Modelling in medication adherence research: A scoping review protocol [version 1; peer review: awaiting peer review]. HRB Open Res 2020, 3:25 (https://doi.org/10.12688/hrbopenres.13056.1)

Safe and Quality Medicines

Mac Avin M, Teeling M, Bennett K. (2020). Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015. BMJ Open. 2020 April 22.10. e035716. 10.1136/bmjopen-2019-035716. DOI: 10.1136/bmjopen-2019-035716

Disease Modelling

Marasigan V, Perry I, Bennett K, Balanda K, Capewell S, O’ Flaherty M, Kabir Z. Explaining the fall in Coronary Heart Disease mortality in the Republic of Ireland between 2000 and 2015 – IMPACT modelling study. Int J Cardiol. 2020 Mar 31. doi: 10.1016/j.ijcard.2020.03.067. PubMed PMID: 32276770

Safe and Quality Medicines

Tecklenborg S, Byrne C, Cahir C, Brown L, Bennett K. Interventions to Reduce Adverse Drug Event-Related Outcomes in Older Adults: A Systematic Review and Meta-analysis. Drugs Aging. 2020 Feb;37(2):91-98. doi: 10.1007/s40266-019-00738-w. Review. Erratum in: Drugs Aging. 2020 Jan 27;:. PubMed PMID: 31919801.

Safe and Quality Medicines

Moriarty F, Bennett K, Kenny RA, Fahey T, Cahir C. Comparing Potentially Inappropriate Prescribing Tools and Their Association With Patient Outcomes. J Am Geriatr Soc. 2020 Mar;68(3):526-534. doi: 10.1111/jgs.16239. Epub 2019 Nov 1. PubMed PMID: 31675114.

Safe and Quality Medicines

Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non-adherence and adverse health outcomes in ageing populations: A systematic review and meta-analysis. Br J Clin Pharmacol.

2019 Nov;85(11):2464-2478. doi: 10.1111/bcp.14075. Epub 2019 Sep 6. Review. PubMed PMID: 31486099; PubMed Central PMCID: PMC6848955. Read More